Profile: Xstelos Holdings Inc (XTLS.PK)
5 Mar 2014
Xstelos Holdings, Inc. (Xstelos) was a wholly owned subsidiary of Footstar, Inc. (Footstar). On January 23, 2012 entered into a Plan of Reorganization (the Plan of Reorganization) with Footstar, Inc. (Footstar), pursuant to which Footstar contributed all of its assets to Xstelos, including its cash, real estate and its 80.5% interest in FCB I Holdings, Inc. (FCB Holdings). On April 5, 2011, the parties completed the CPEX Transaction pursuant to the CPEX Transaction Agreement. In the CPEX Transaction, the Company acquired CPEX Pharmaceuticals, Inc. (CPEX), a specialty pharmaceutical company. As a result of the CPEX Transaction, an indirect majority-owned subsidiary of Xstelos Corp merged with and into CPEX, with CPEX surviving as a wholly owned subsidiary of FCB Holdings.
CPEX is an indirectly, majority-owned subsidiary of Xstelos. CPEX has United States and international patents and other rights to technology that facilitates the absorption of drugs. Its platform drug delivery technology is based upon CPE-215, which enhances permeation and absorption of pharmaceutical molecules across biological membranes, such as the skin, nasal mucosa and eye. CPEX’s product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. The Company earns royalty revenues on sales of Testim, a testosterone gel that incorporates its CPE-215 drug delivery technology.
The Company competes with Archimedes Pharma Ltd, AstraZeneca PLC, Bayer Consumer Care, GlaxoSmithKline plc, Pfizer, Inc., Alkermes Inc., Unigene Inc., Generex Biotechnology Corporation, Emisphere Technologies, Inc. and Coremed Corporation.
Xstelos Holdings Inc
630 Fifth Avenue
NEW YORK NY 10020